HeLa cells prelabelled with [3H]lysoplatelet-activating factor (lyso-PAF) accumulated phosphatidic acid (PtdOH) when incubated in the presence of either propranolol (an inhibitor of PtdOH phosphohydrolase) or phorbol ester. In the presence of ethanol, phorbol ester but not propranolol stimulated the accumulation of phosphatidylethanol, an index of phospholipase D activity. Incubation of cells with [3H]lyso-PAF led to a rapid accumulation of label in diacylglycerol (DG) followed by a delayed accumulation in PtdOH. It is concluded that propranolol-induced PtdOH accumulation is derived from DG by DG kinase and does not involve phospholipase D.
INTRODUCTION
In many animal cells interaction of surface receptors with agonists which leads to activation of protein kinase C, or with phorbol esters which activates protein kinase C directly, results in the hydrolysis of phosphatidylcholine (PtdCho) by phospholipase D [1, 2] . This can be detected as the release of [3H]choline from cells in which phospholipid pools have been prelabelled with [3H]choline [3] [4] [5] , or by measuring the phospholipase Dcatalysed accumulation of phosphatidylalcohol in the presence of a primary alcohol [6] [7] [8] [9] . Much less is known about the turnover of PtdCho in unstimulated cells. In a recent report we suggested that this turnover involves the sequential actions of phospholipase C, diacylglycerol (DG) kinase and PtdOH phosphohydrolase [5] . Incubation of HeLa cells with propranolol, an inhibitor of PtdOH phosphohydrolase [10] Table 2 ). Incubation of the prelabelled cells with propranolol or with phorbol 12-myristate i3-acetate (PMA) resulted in the accumulation of labelled PtdOH (experiment 1, Table 1 [14] . The accumulation of this relatively stable derivative has been widely used as an index of phospholipase D activity. As shown in Table   1 (experiment 2), propranolol did not stimulate PtdEth accumulation. On the other hand PtdEth accumulation was stimulated by PMA, a known activator of protein kinase C, a phenomenon which has been extensively documented [2] .
The above results indicate that PtdOH formation from preformed PtdCho involves an indirect pathway. Evidence that PtdOH formation was preceded by the accumulation of DG was obtained in an experiment in which radioactivity associated with both products was followed with time of incubation in the presence of [3H]lyso-PAF (Table 2) . Propranolol was included in the incubations to inhibit PtdOH phosphohydrolase activity and limit further metabolism of the accumulated PtdOH. It is clear that incubation with [3H]lyso-PAF resulted in the rapid appearance of label in DG, but that labelled PtdOH could only be detected after a lag period of 2-5 min. The effect of propranolol on DG-and PtdOH-labelling in cells prelabelled with [3H]lyso-PAF was also determined (Table 3) . Incubation with propranolol resulted in the accumulation of radioactive PtdOH and at the same time a decrease in DG labelling. These results also support the conclusion that PtdCho turnover involves both DG kinase and PtdOH phosphohydrolase.
The present results support the proposal that PtdCho turnover in confluent HeLa cells is initiated by phospholipase C, resulting in the rapid formation of DG which is then converted into PtdOH by DG kinase. An important assumption made in reaching this conclusion is that the ether derivatives (lyso-PAF and PtdCho) are metabolically stable, and can not be converted into breakdown products which could be incorporated into the ester form of PtdOH by de novo biosynthesis. In particular, some cells contain an alkylglycerol mono-oxygenase [15] which catalyses the oxidative cleavage of the alkyl group to a fatty aldehyde. Alkylglycerol could be formed from lyso-PAF by the sequential actions of lysophospholipase D and lyso-PtdOH phosphohydrolase [16] or from PtdCho by the actions of phospholipase C and DG lipase. In the present experiments, after prelabelling the cells with lyso-PAF, 5 % of the radioactivity associated with PtdCho was ester-linked (results not shown; determined as described previously [9] ), indicating that some metabolism of the ether phospholipid had occurred. This was further accentuated in PtdOH where about 40 % of the radioactivity which accumulated in the presence of propranolol was in the ester form with the remainder as the ether derivative (results not shown). While this result clearly establishes that a significant proportion of the accumulated PtdOH was derived from preformed phospholipid, it stresses the dangers of assuming that lyso-PAF is metabolically stable in all cells.
Given the prelabelling protocol used in the present experiments it is likely that labelled PtdCho would initially accumulate in the plasma membrane. However, previous studies have indicated that when Chinese hamster fibroblasts were incubated with a fluorescent derivative of PtdCho at 37°C a significant fraction of the preformed lipid was retained in the plasma membrane, but that some lipid rapidly migrated to intracellular membranes [17] . If a similar situation exists in HeLa cells, it would be predicted that cells prelabelled with lyso-PAF at 37°C will accumulate PtdCho in both the plasma membrane and in other membrane systems. Consequently, it is uncertain which cellular phospholipid pools are involved in the pathways described in the present report. This is clearly of importance and the subcellular distributions of PtdCho metabolites generated as a consequence of turnover, or following activation of phospholipase D with phorbol esters should be compared. 
